Prosecution Insights
Last updated: April 19, 2026

Examiner: GROSS, CHRISTOPHER M

Tech Center 1600 • Art Units: 1612 1636 1639 1675 1678 1684

This examiner grants 63% of resolved cases

Performance Statistics

63.0%
Allow Rate
+3.0% vs TC avg
688
Total Applications
+41.2%
Interview Lift
1501
Avg Prosecution Days
Based on 651 resolved cases, 2023–2026

Rejection Statute Breakdown

3.2%
§101 Eligibility
27.6%
§102 Novelty
31.9%
§103 Obviousness
23.1%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17811486 HIGH-THROUGHPUT AND HIGHLY MULTIPLEXED IMAGING WITH PROGRAMMABLE NUCLEIC ACID PROBES Non-Final OA President and Fellows of Harvard College
18940636 PROCESSES AND SYSTEMS FOR PREPARATION OF NUCLEIC ACID SEQUENCING LIBRARIES AND LIBRARIES PREPARED USING SAME Non-Final OA 10x Genomics, Inc.
18074081 METHOD FOR TRANSPOSASE MEDIATED SPATIAL TAGGING AND ANALYZING GENOMIC DNA IN A BIOLOGICAL SAMPLE Non-Final OA 10x Genomics, Inc.
16817458 CROSS-LINKED EPITOPES AND METHODS OF USE THEREOF Final Rejection REGENERON PHARMACEUTICALS, INC.
18396156 Digital Analysis of Circulating Tumor Cells in Blood Samples Non-Final OA The General Hospital Corporation
17287202 PROFILING OF RHEUMATOID ARTHRITIS AUTOANTIBODY REPERTOIRE AND PEPTIDE CLASSIFIERS THEREFOR Final Rejection ROCHE SEQUENCING SOLUTIONS, INC.
18659813 MACROMOLECULE ANALYSIS EMPLOYING NUCLEIC ACID ENCODING Final Rejection Encodia, Inc.
17642800 Micro-Radiobinding Assays for Ligand Screening Final Rejection AC Immune SA
17182044 GENE EXPRESSION-BASED BIOMARKER FOR THE DETECTION AND MONITORING OF BRONCHIAL PREMALIGNANT LESIONS Final Rejection Trustees of Boston University
17297944 METHOD FOR PREDICTING THE RESPONSE TO CANCER IMMUNOTHERAPY IN CANCER PATIENTS Non-Final OA Charité - Universitätsmedizin Berlin
18250816 SYNTHETIC LETHALITY-MEDIATED PRECISION ONCOLOGY VIA TUMOR TRANSCRIPTOME Non-Final OA The United States of America, as Represented by the Secretary, Dept. of Health and Human Services
18637241 METHODS, SYSTEMS, AND COMPOSITIONS FOR COUNTING NUCLEIC ACID MOLECULES Non-Final OA Enumera Molecular, Inc.
17636288 METHOD OF QUALIFYING A SUBGROUP OF TARGET BINDING BIOMOLECULES FROM A LARGER GROUP OF TARGET BINDING BIOMOLECULES FOR ANALYSIS Final Rejection Cytiva Sweden AB
17370819 METHODS AND COMPOSITIONS FOR THE DIAGNOSIS OF SEPSIS USING GAMMA PEPTIDE NUCLEIC ACIDS Non-Final OA HELIXBIND, INC.
18339429 METHODS OF IDENTIFYING COMPOUNDS FOR INDUCING PROTEIN-PROTEIN INTERACTION Final Rejection Oncopia Therapeutics, Inc. d/b/a/ SK Life Science Labs
17702643 VARIANT NUCLEIC ACID LIBRARIES FOR TIGIT Non-Final OA Twist Bioscience Corporation
18025107 ARRAY, SOAKING SOLUTIONS AND METHOD OF SELECTING SOAKING CONDITIONS FOR SMALL MOLECULES IN BIOLOGICAL MACROMOLECULAR CRYSTALS Non-Final OA CRYSTALSFIRST GMBH
18025100 ARRAY, SOAKING SOLUTIONS AND METHOD OF SELECTING SOAKING CONDITIONS FOR SMALL MOLECULES IN BIOLOGICAL MACROMOLECULAR CRYSTALS Non-Final OA CRYSTALSFIRST GMBH
18025103 ARRAY, SOAKING SOLUTIONS AND METHOD OF SELECTING SOAKING CONDITIONS FOR SMALL MOLECULES IN BIOLOGICAL MACROMOLECULAR CRYSTALS Non-Final OA CRYSTALSFIRST GMBH
18060187 METHOD AND SYSTEM FOR GENERATING A PLURALITY OF ANTIBODY SEQUENCES OF A TARGET FROM ONE OR MORE FRAMEWORK REGIONS Non-Final OA Innoplexus AG
18060218 METHOD AND SYSTEM FOR GENERATING A PLURALITY OF ANTIBODY SEQUENCES Non-Final OA Innoplexus AG
18008766 SUBSTRATE FOR IMMOBILIZING SUBSTANCE, AND USE THEREOF Non-Final OA R-NANOBIO CO. LTD.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month